Page last updated: 2024-08-18

pyrroles and Neuroendocrine Tumors

pyrroles has been researched along with Neuroendocrine Tumors in 110 studies

Research

Studies (110)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (7.27)	29.6817
2010's	100 (90.91)	24.3611
2020's	2 (1.82)	2.80

Authors

Authors	Studies
Aburjania, Z; Chen, H; Jang, S; Jaskula-Sztul, R; Nadkarni, DH; Rose, JB; Velu, SE; Whitt, JD	1
Fukazawa, E; Harada, K; Ichimata, M; Kagawa, Y; Katayama, R; Kobayashi, T; Matsuyama, F; Nishiyama, S; Toshima, A; Yamagami, T	1
Bertani, E; Bonomo, G; Cella, C; Fazio, N; Funicelli, L; Gibelli, B; Grana, C; Lambrescu, I; Martins, D; Pisa, E; Ravizza, D; Ribero, D; Rubino, M; Spada, F; Zerini, D	1
Broder, MS; Chang, E; Neary, MP; Reddy, SR	1
Chen, J; Chen, M; Feng, S; Jin, K; Li, J; Shao, C; Tan, H; Wang, W; Wang, Y; Xue, L; Yang, Q; Yu, X; Zhang, P	1
Bill, R; Blank, A; Krebs, P; Marinoni, I; Normand, L; Pantasis, S; Perren, A; Tschan, MP; Wiedmer, T	1
Avniel-Polak, S; Gross, DJ; Grozinsky-Glasberg, S; Uri, I	1
Antonuzzo, L; Badalamenti, G; Berardi, R; Bongiovanni, A; Brighi, N; Brizzi, MP; Campana, D; Carnaghi, C; Catena, L; Delle Fave, G; Faggiano, A; Falconi, M; Fazio, N; Femia, D; Gelsomino, F; Gritti, S; Ibrahim, T; Marconcini, R; Panzuto, F; Partelli, S; Pusceddu, S; Ricci, S; Rinzivillo, M; Schinzari, G; Spada, F; Spallanzani, A	1
Akahoshi, K; Akashi, T; Ban, D; Kudo, A; Mitsunori, Y; Mizuno, Y; Ogawa, K; Ogura, T; Ono, H; Tanabe, M; Tanaka, S; Tateishi, U	1
Mankal, P; O'Reilly, E	1
Libutti, SK; Saif, MW; Stevenson, R	1
Boussaha, T; Lepere, C; Rougier, P; Taieb, J	1
Chiu, WY; Hung, IF; Mok, MY; Shea, YF; Yau, CC	1
Bisht, S; Brossart, P; Feldmann, G	1
Kulke, MH; Lagunes, DR; Yao, JC	1
Chen, HR; Li, P; Lin, LZ; Pang, LJ	1
Francois, R; Hochwald, SN; Iyer, R; Seshadri, M; Zajac-Kaye, M; Zhang, J	1
Khagi, S; Saif, MW	1
Imai, H; Kageyama, S; Katayama, N; Matsuoka, N; Mizuno, T; Oda, H; Saito, K; Sugawara, Y; Tamaru, S; Uchida, K; Yamashita, Y	1
Tóth, M	1
Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M	1
Castellano, D; Faivre, S; González, E; Salazar, R; Strosberg, J	1
Faivre, S; Ishak, KJ; Korytowsky, B; Proskorovsky, I; Sandin, R; Valle, J	1
Amiel, SA; Aylwin, SJ; Huda, MS; Ross, P	1
Jiang, CY; Wang, HW; Wang, W	1
Karampelas, IN; Saif, MW; Syrigos, KN	1
Faivre, S; Grande, E; Hubner, RA; Raymond, E; Valle, JW	1
Raj, N; Reidy-Lagunes, D	1
Boratyn-Nowicka, A; Ćwikła, JB; Jarząb, B; Kos-Kudła, B; Michalik, B; Nawrocki, S; Piątek, M; Rogowski, W; Szabłowska-Siwik, S; Wachuła, E; Zemczak, A	1
Berman, A; Brzezniak, C; Carter, CA; Giaccone, G; Guha, U; Lee, MJ; Lee, S; Ling, A; Loehrer, PJ; Meltzer, P; Rajan, A; Spittler, AJ; Steinberg, SM; Szabo, E; Thomas, A; Tomita, Y; Trepel, JB; Wang, Y	1
Marx, A; Weis, CA	1
Carley, W; DePrimo, SE; Harmon, CS; Heymach, JV; Huang, X; Khajavi, M; Kulke, MH; Lenz, HJ; Lin, E; Meropol, NJ; Tye, L; Wang, X; Wu, HK; Zurita, AJ	1
Kulke, MH	2
Cottle-Delisle, C; Kebebew, E; Marx, S; Meltzer, P; Merkel, R; Neychev, V; Nilubol, N; Pacak, K; Steinberg, SM; Yao, J	1
Cella, CA; Elgendy, M; Fazio, N; Galdy, S; Minucci, S; Murgioni, S; Ravenda, PS; Spada, F; Zampino, MG	1
Kato, S	1
Grandhi, MS; Lafaro, KJ; Pawlik, TM	1
Kunz, PL; Phan, AT; Reidy-Lagunes, DL	1
Berardi, R; Caramanti, M; Cascinu, S; Falconi, M; Morgese, F; Onofri, A; Pagliaretta, S; Partelli, S; Polenta, V; Rinaldi, S; Torniai, M	1
Führer, D; Kühl, H; Lahner, H; Lehmann, N; Poeppel, TD; Rinke, A; Unger, N	1
Allen, E; Hanahan, D; Li, L; Miéville, P; Peng, MW; Saghafinia, S; Warren, CM	1
Papaxoinis, G; Saif, MW; Syrigos, K	1
Dekeister, K; Durbec, M; Graillot, E; Scoazec, JY; Walter, T	1
Dave, B; Phan, AT	1
Ito, T; Jensen, RT; Lee, L	1
Howe, JR; Maxwell, JE; Sherman, SK	1
Capozzi, M; DE Divitiis, C; Ottaiano, A; Romano, GM; Tafuto, S; Tatangelo, F; VON Arx, C	1
Bang, YJ; Borbath, I; Castellano, D; Chen, JS; Faivre, S; Hammel, P; Ishak, KJ; Lee, SH; Lombard-Bohas, C; Lu, DR; Metrakos, P; Niccoli, P; Patyna, S; Raoul, JL; Raymond, E; Ruszniewski, P; Seitz, JF; Smith, D; Valle, JW; Van Cutsem, E; Vinik, A	1
Bang, YJ; Bottomley, A; Chao, RC; Hörsch, D; Korytowsky, B; Metrakos, P; Mundayat, R; Raoul, JL; Raymond, E; Reisman, A; Valle, JW; Vinik, A; Wang, Z	1
Chae, H; Chang, HM; Cho, H; Hong, SM; Hong, YS; Kang, YK; Kim, KP; Kim, SC; Kim, TW; Ryoo, BY; Ryu, MH; Song, MJ; Yoo, C	1
Adham, M; Forestier, J; Foulfoin, M; Graillot, E; Hervieu, V; Lombard-Bohas, C; Robinson, P; Rousset, P; Scoazec, JY; Walter, T	1
Angelousi, A; de Herder, W; Kaltsas, G; Kaltsatou, M; Kamp, K; O'Toole, D	1
Chen, J; Chen, M; Feng, ST; Huang, K; Li, ZP; Lin, Y; Luo, Y; Xu, L	1
Baum, CM; Bergsland, E; Fuchs, CS; Huang, X; Kulke, MH; Lenz, HJ; Li, JZ; Meropol, NJ; Picus, J; Posey, J; Ryan, DP; Stuart, K; Tye, L	1
Bajetta, E; Guadalupi, V; Procopio, G	1
Chan, JA; Kulke, MH	1
Chun, MG; Golub, TR; Hanahan, D; Libutti, SK; Lu, J; Nakakura, EK; Olson, P; Shai, A; Wang, Y; Zhang, H	1
Faivre, S; Hammel, P; Raymond, E; Ruszniewski, P	1
Unno, M	1
Dimou, AT; Saif, MW; Syrigos, KN	1
Auernhammer, CJ; Brand, S; Göke, B; Lichtl, J; Rüden, Jv; Spöttl, G; Zitzmann, K	1
Eriksson, B	1
Bang, YJ; Blanckmeister, C; Borbath, I; Chao, R; Chen, JS; Dahan, L; Hammel, P; Hörsch, D; Lombard-Bohas, C; Lu, DR; Metrakos, P; Patyna, S; Raoul, JL; Raymond, E; Ruszniewski, P; Smith, D; Valle, J; Van Cutsem, E; Vinik, A; Wiedenmann, B	1
Delle Fave, G; Jensen, RT	1
Angeles Vaz, M; Carrato, A; García de Paredes, ML; Grande, E; Guillén, C; José Díez, J; Longo, F; Pachón, V	1
Saif, MW; Strimpakos, AS; Syrigos, KN	1
Hanahan, D; Tuveson, D	1
Libutti, SK; Spiegel, AM	1
Peres, J	1
Kleijn, SA; van der Veldt, AA	1
Barriuso, J; Castellano, D; Grande, E	1
Berruti, A; Pia, A; Terzolo, M	1
Coriat, R; Goldwasser, F; Mir, O	1
Choi, HJ; Jung, HS; Kim, MJ; Kim, SY; Kim, TM; Lee, Y; Park, KS	1
Yim, KL	1
Baltogiannis, G; Katsios, C; Roukos, DH	1
Deeks, ED; Raymond, E	1
Chu, GC; Hanahan, D; Nolan-Stevaux, O; Olson, P; Perry, SR	1
Davis, DW; Fuller, GN; Gombos, DS; Jonasch, E; Matin, SF; McCutcheon, IE; Smith, LA; Tannir, NM; Waguespack, SG; Wen, S	1
Hubner, RA; Valle, JW	1
Campos, TL; Choi, J; Han, G; Kvols, LK; Schell, MJ; Strosberg, JR; Valone, TL; Weber, JM	1
Dong, M; Phan, AT; Yao, JC	1
Gao, F; Sita-Lumsden, A; Visvardis, EE; Waxman, J	1
Reidy-Lagunes, D; Thornton, R	1
Bussolino, F; Capano, S; Casanovas, O; Giacca, M; Giraudo, E; Maione, F; Regano, D; Serini, G; Zentilin, L	1
Heymach, JV; Mateo, J; Zurita, AJ	1
Bouattour, M; Bruno, O; Couvelard, A; Dreyer, C; Faivre, S; Hentic, O; Raymond, E; Ronot, M; Serrate, C; Vilgrain, V	1
Capdevila, J; Tabernero, J	1
Barck, KH; Cao, TC; Carano, RA; Cheng, JH; Couto, SS; Eastham-Anderson, J; Ferrara, N; Foreman, O; Forrest, WF; Hamilton, P; Ho, CC; Johnson, L; Jubb, AM; Kasman, I; Lima, A; Long, JE; McNutt, A; Molina, R; Nannini, MA; Reslan, HB; Singh, M	1
Dreyer, C; Faivre, S; Hammel, P; Hentic, O; Maatescu, C; Raymond, E; Ruszniewski, P	1
Raymond, E; Ruszniewski, P	1
Boninsegna, L; Crippa, S; Falconi, M; Partelli, S	1
Xu, JM	1
Halfdanarson, TR; Naraev, BG; Strosberg, JR	1
Blumenthal, GM; Cortazar, P; Justice, R; Murgo, A; Pazdur, R; Sridhara, R; Tang, S; Zhang, JJ	1
Casciano, R; Chulikavit, M; Garrison, LP; Liu, Z; Perrin, A; Wang, X	1
Dreyer, C; Faivre, S; Raymond, E	1
Couvelard, A; de Gramont, A; Faivre, S; Hammel, P; Neuzillet, C; Raymond, E; Serova, M; Tijeras-Raballand, A	1
Igarashi, H; Ito, T; Jensen, RT; Takayanagi, R	1
Chiu, J; Cho, WY; Lang, B; Leung, R; Shek, T; Wong, H; Yat, WK; Yau, LC; Yau, T	1
Baum, RP; Bert, T; Hommann, M; Hörsch, D; Kaemmerer, D; Petrovitch, A; Schrader, J; Zaknun, J	1
Chao, RC; Hara, K; Hashigaki, S; Igarashi, H; Imamura, M; Ito, T; Kimura, N; Kondo, S; Mizuno, N; Morizane, C; Murakami, M; Nishida, T; Ohki, E; Okusaka, T; Sawaki, A; Yamao, K	1
Barna, ME; Pastorello, M; Uomo, I	1
Peng, L; Schwarz, RE	1
Öberg, K	1
Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schöfl, C	1
Adams, VR; Leggas, M	1
Polyzos, A	1

Reviews

42 review(s) available for pyrroles and Neuroendocrine Tumors

Article	Year
Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. Targeted oncology, 2017, Volume: 12, Issue:5 Topics: Antineoplastic Agents; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2017
Update in the Therapy of Advanced Neuroendocrine Tumors. Current treatment options in oncology, 2017, 11-16, Volume: 18, Issue:12 Topics: Combined Modality Therapy; Cytoreduction Surgical Procedures; Everolimus; Humans; Indoles; Intestinal Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Somatostatin; Stomach Neoplasms; Sunitinib	2017
Sunitinib malate for the treatment of pancreas malignancies--where does it fit? Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:6 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2013
Novel agents in gastroenteropancreatic neuroendocrine tumors. JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drugs, Investigational; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib	2013
Digestive neuroendocrine tumors (DNET): the era of targeted therapies. Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:2 Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bevacizumab; Clinical Trials as Topic; Digestive System Neoplasms; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2013
Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2013
Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. The oncologist, 2013, Volume: 18, Issue:5 Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib	2013
Current understanding of the molecular biology of pancreatic neuroendocrine tumors. Journal of the National Cancer Institute, 2013, Jul-17, Volume: 105, Issue:14 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Hypoxia; Co-Repressor Proteins; Cyclin-Dependent Kinase Inhibitor p18; Disease Progression; Disease-Free Survival; Everolimus; Gene Knock-In Techniques; Gene Knockout Techniques; Genetic Predisposition to Disease; Humans; Indoles; Islets of Langerhans; Molecular Chaperones; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Neuroendocrine Tumors; Nuclear Proteins; Octreotide; Pancreatic Neoplasms; Proto-Oncogene Proteins; Pyrroles; Receptor, Notch1; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2013
[Drug therapy for neuroendocrine tumours]. Orvosi hetilap, 2013, Sep-29, Volume: 154, Issue:39 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemoembolization, Therapeutic; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Liver Neoplasms; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Octreotide; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sirolimus; Somatostatin; Sunitinib	2013
[Targeted therapies, prognostic and predictive factors in endocrine oncology]. Annales d'endocrinologie, 2013, Volume: 74 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome	2013
Pancreatic NETs: where do we stand now? Cancer metastasis reviews, 2014, Volume: 33, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome; Tumor Suppressor Proteins	2014
Targeted agents in treatment of neuroendocrine tumors of pancreas. JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4 Topics: Antineoplastic Agents; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Survival Analysis; Treatment Outcome	2014
Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors. Pancreas, 2014, Volume: 43, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Differentiation; Chemoradiotherapy; Clinical Trials as Topic; Drugs, Investigational; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radioisotopes; Sirolimus; Somatostatin; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2014
Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside. Cancer treatment reviews, 2015, Volume: 41, Issue:9 Topics: Angiogenesis Inducing Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Synergism; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Translational Research, Biomedical; Vascular Endothelial Growth Factor A	2015
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2015
Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2015, Volume: 19, Issue:12 Topics: Antineoplastic Agents; Humans; Indoles; Intestinal Neoplasms; Liver Neoplasms; Liver Transplantation; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Pyrroles; Stomach Neoplasms; Sunitinib	2015
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review. Critical reviews in oncology/hematology, 2016, Volume: 98 Topics: Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Liver Neoplasms; Neuroendocrine Tumors; Pyrroles; Somatostatin; Sunitinib	2016
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. Cancer medicine, 2016, Volume: 5, Issue:10 Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome	2016
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:16 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Pyrroles; Somatostatin; Sunitinib; Syndrome; Treatment Outcome	2016
Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-15, Volume: 22, Issue:20 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; CD47 Antigen; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases	2016
Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors. Anticancer research, 2016, Volume: 36, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2016
Progress in the treatment of neuroendocrine tumors. Current oncology reports, 2009, Volume: 11, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib	2009
[Recent progress in the molecular-targeting treatment of neuroendocrine tumors]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2010, Volume: 107, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Drug Delivery Systems; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib	2010
Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP : Journal of the pancreas, 2010, Mar-05, Volume: 11, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Clinical Trials as Topic; Combined Modality Therapy; Congresses as Topic; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sirolimus; Sunitinib	2010
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? Current opinion in oncology, 2010, Volume: 22, Issue:4 Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome	2010
Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocrine, 2011, Volume: 40, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Endocrine Gland Neoplasms; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Molecular Targeted Therapy; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2011
Sunitinib for advanced pancreatic neuroendocrine tumors. Expert review of anticancer therapy, 2011, Volume: 11, Issue:12 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2011
New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-01, Volume: 18, Issue:7 Topics: Antineoplastic Agents; Disease-Free Survival; Drug Therapy; Everolimus; Humans; Indoles; Models, Biological; Neuroendocrine Tumors; Octreotide; Pancreas; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2012
Advances in the treatment of pancreatic neuroendocrine tumours. QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:9 Topics: Antineoplastic Agents; Disease-Free Survival; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib	2012
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different? Current oncology reports, 2012, Volume: 14, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes	2012
Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Molecular diagnosis & therapy, 2012, Jun-01, Volume: 16, Issue:3 Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Interleukin-8; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors. Cancer discovery, 2011, Volume: 1, Issue:3 Topics: Clinical Trials as Topic; Drug Discovery; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib	2011
Sunitinib in pancreatic neuroendocrine tumors. Targeted oncology, 2012, Volume: 7, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2012
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology, 2012, Volume: 83, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Targeted oncology, 2012, Volume: 7, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan]. Fukuoka igaku zasshi = Hukuoka acta medica, 2012, Volume: 103, Issue:7 Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immunosuppressive Agents; Indoles; Japan; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Somatostatin; Streptozocin; Sunitinib; Temozolomide	2012
Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy. Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Radiopharmaceuticals; Signal Transduction; Sirolimus; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases	2013
Pancreatic neuroendocrine neoplasms. Minerva gastroenterologica e dietologica, 2012, Volume: 58, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromogranin A; Endosonography; Everolimus; Germany; Hepatectomy; Humans; Incidence; Indoles; Liver Transplantation; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Prevalence; Prognosis; Pyrroles; Sirolimus; Somatostatin; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2012
Pancreatic neuroendocrine tumors: signal pathways and targeted therapies. Current molecular medicine, 2013, Volume: 13, Issue:3 Topics: Antineoplastic Agents; Everolimus; Humans; Immunosuppressive Agents; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2013
Systemic therapy for advanced pancreatic neuroendocrine tumors. Seminars in oncology, 2013, Volume: 40, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Somatostatin; Sunitinib; Treatment Outcome	2013
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clinical therapeutics, 2007, Volume: 29, Issue:7 Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lactation; Lung Neoplasms; Neuroendocrine Tumors; Pregnancy; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib	2007
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. The Journal of steroid biochemistry and molecular biology, 2008, Volume: 108, Issue:3-5 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib	2008

Trials

13 trial(s) available for pyrroles and Neuroendocrine Tumors

Article	Year
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Prognosis; Pyrroles; Sunitinib; Survival Rate; Thymoma; Thymus Neoplasms	2015
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. British journal of cancer, 2015, Mar-31, Volume: 112, Issue:7 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoid Tumor; Cytokines; Disease-Free Survival; Female; Humans; Indoles; Leukocyte Count; Monocytes; Neuroendocrine Tumors; Pyrroles; Sunitinib; Treatment Outcome	2015
Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical tria BMJ open, 2015, May-19, Volume: 5, Issue:5 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cytoreduction Surgical Procedures; Digestive System Neoplasms; Disease-Free Survival; Everolimus; Gastrointestinal Neoplasms; Gastrointestinal Tract; Genotype; Humans; Indoles; Mutation; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Prospective Studies; Pyrroles; Research Design; Sunitinib	2015
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Feb-01, Volume: 28, Issue:2 Topics: Antineoplastic Agents; Cross-Sectional Studies; Disease-Free Survival; Double-Blind Method; Humans; Indoles; Kaplan-Meier Estimate; Neuroendocrine Tumors; Pancreatic Neoplasms; Proportional Hazards Models; Pyrroles; Sunitinib; Survival Rate	2017
Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. Targeted oncology, 2016, Volume: 11, Issue:6 Topics: Antineoplastic Agents; Female; Humans; Indoles; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Reported Outcome Measures; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib	2016
Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-10, Volume: 26, Issue:20 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoid Tumor; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Quality of Life; Risk Assessment; Single-Blind Method; Sunitinib; Survival Analysis; Treatment Outcome	2008
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England journal of medicine, 2011, Feb-10, Volume: 364, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Double-Blind Method; Female; Humans; Indoles; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Sunitinib	2011
Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2011, Oct-01, Volume: 25, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Indoles; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib	2011
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:12 Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Hemangioblastoma; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pilot Projects; Pyrroles; Radiography; Sunitinib; Treatment Outcome; von Hippel-Lindau Disease; Young Adult	2011
A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9 Topics: Acrylic Resins; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Embolization, Therapeutic; Female; Gelatin; Hepatic Artery; Humans; Indoles; Intestinal Neoplasms; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neuroendocrine Tumors; Proportional Hazards Models; Pyrroles; Statistics, Nonparametric; Sunitinib; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A	2012
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. The oncologist, 2012, Volume: 17, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Approval; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; United States; United States Food and Drug Administration	2012
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Investigational new drugs, 2013, Volume: 31, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Asian People; Biomarkers, Tumor; Chromogranin A; Female; Gastrins; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome	2013
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. The Journal of steroid biochemistry and molecular biology, 2008, Volume: 108, Issue:3-5 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib	2008

Other Studies

56 other study(ies) available for pyrroles and Neuroendocrine Tumors

Article	Year
Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells. Molecules (Basel, Switzerland), 2020, Oct-26, Volume: 25, Issue:21 Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Neuroendocrine Tumors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrroles	2020
Long-term survival in a dog with primary hepatic neuroendocrine tumor treated with toceranib phosphate. The Journal of veterinary medical science, 2021, Oct-05, Volume: 83, Issue:10 Topics: Animals; Autopsy; Dog Diseases; Dogs; Indoles; Male; Neuroendocrine Tumors; Pyrroles	2021
Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors. Pancreas, 2017, Volume: 46, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cost of Illness; Everolimus; Humans; Indoles; Middle Aged; Molecular Targeted Therapy; Nausea; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sunitinib; Thrombocytopenia; Vomiting; Young Adult	2017
Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China. Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:3 Topics: Adult; Aged; China; Female; Humans; Indoles; Male; Middle Aged; Neuroendocrine Tumors; Pyrroles; Retrospective Studies; Sunitinib; Young Adult	2017
Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism. Molecular cancer therapeutics, 2017, Volume: 16, Issue:11 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockdown Techniques; Humans; Indoles; Lysosomal-Associated Membrane Protein 2; Lysosomes; Mice; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2017
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2018, Volume: 18, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Humans; Indoles; Italy; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome	2018
Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Proportional Hazards Models; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Young Adult	2018
Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour. Journal of clinical pharmacy and therapeutics, 2013, Volume: 38, Issue:4 Topics: Humans; Hyperammonemia; Indoles; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2013
Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor. Future oncology (London, England), 2013, Volume: 9, Issue:6 Topics: Disease-Free Survival; Female; Humans; Indoles; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Pyrroles; Sunitinib	2013
Neuroendocrine tumors: treatment updates. JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Everolimus; Humans; Indoles; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Sirolimus; Stomach Neoplasms; Sunitinib; Treatment Outcome	2013
[A case report of a well-differentiated neuroendocrine tumor in which sunitinib treatment resulted in stable disease]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:9 Topics: Antineoplastic Agents; Cell Differentiation; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pyrroles; Sunitinib	2013
Methods for adjusting for bias due to crossover in oncology trials. PharmacoEconomics, 2014, Volume: 32, Issue:6 Topics: Antineoplastic Agents; Bias; Cost-Benefit Analysis; Cross-Over Studies; Humans; Indoles; Kaplan-Meier Estimate; Models, Statistical; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib	2014
Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes. Diabetes care, 2014, Volume: 37, Issue:5 Topics: Antineoplastic Agents; Diabetes Mellitus, Type 1; Fatal Outcome; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Indoles; Insulin Aspart; Insulin Glargine; Insulin, Long-Acting; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2014
Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome. Journal of clinical gastroenterology, 2015, Volume: 49, Issue:1 Topics: Adult; Antineoplastic Agents; Female; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; von Hippel-Lindau Disease	2015
Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer treatment reviews, 2014, Volume: 40, Issue:10 Topics: Antineoplastic Agents; Cardiovascular Diseases; Drug Administration Schedule; Fatigue; Hand-Foot Syndrome; Humans; Indoles; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Pyrroles; Stomatitis; Sunitinib; Thyroid Diseases	2014
Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report. Endokrynologia Polska, 2014, Volume: 65, Issue:6 Topics: Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Indoles; Leukopenia; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2014
Sunitinib in thymic carcinoma: enigmas still unresolved. The Lancet. Oncology, 2015, Volume: 16, Issue:2 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Pyrroles; Sunitinib; Thymoma; Thymus Neoplasms	2015
Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-10, Volume: 33, Issue:14 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Diarrhea; Drug Administration Schedule; Everolimus; Humans; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Mitotic Index; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Somatostatin; Sunitinib; Tomography, X-Ray Computed	2015
New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:5 Suppl 5 Topics: Antineoplastic Agents; Everolimus; Hormones; Humans; Indoles; Intestinal Neoplasms; Intestines; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Pancreas; Pancreatic Neoplasms; Pyrroles; Somatostatin; Stomach; Stomach Neoplasms; Sunitinib	2015
Sunitinib Efficacy in Patients with Advanced pNET in Clinical Practice. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2016, Volume: 48, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Indoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Practice Patterns, Physicians'; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome	2016
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell reports, 2016, 05-10, Volume: 15, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glycolysis; Humans; Imidazoles; Indazoles; Indoles; Intestinal Neoplasms; Lactic Acid; Membrane Transport Proteins; Mice; Models, Biological; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Stomach Neoplasms; Sunitinib; TOR Serine-Threonine Kinases; Up-Regulation	2016
Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents. Discovery medicine, 2016, Volume: 21, Issue:117 Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Grading; Neovascularization, Pathologic; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Signal Transduction; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins	2016
Sunitinib-induced sudden hearing loss. Investigational new drugs, 2016, Volume: 34, Issue:6 Topics: Clinical Trials, Phase II as Topic; Female; Hearing Loss, Sudden; Humans; Indoles; Middle Aged; Neuroendocrine Tumors; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Tinnitus; Vertigo	2016
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib	2017
Treatment of metastatic pancreatic neuroendocrine tumors: relevance of ENETS 2016 guidelines. Endocrine-related cancer, 2017, Volume: 24, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Everolimus; Female; Guidelines as Topic; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Pyrroles; Retrospective Studies; Societies, Medical; Sunitinib; Young Adult	2017
Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments. Neuroendocrinology, 2017, Volume: 105, Issue:4 Topics: Antineoplastic Agents; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Severity of Illness Index; Sunitinib; Treatment Outcome	2017
Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria? BMC cancer, 2017, 02-23, Volume: 17, Issue:1 Topics: Adult; Antineoplastic Agents; Female; Humans; Indoles; Intestinal Neoplasms; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2017
Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-10, Volume: 27, Issue:2 Topics: Antineoplastic Agents; Humans; Indoles; Neuroendocrine Tumors; Pyrroles; Sunitinib	2009
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes & development, 2009, Sep-15, Volume: 23, Issue:18 Topics: Angiogenesis Inhibitors; Animals; Cell Differentiation; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mice; Mice, Inbred C57BL; MicroRNAs; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Tumor Cells, Cultured	2009
Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Targeted oncology, 2009, Volume: 4, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoid Tumor; Cell Line, Tumor; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Melphalan; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Procarbazine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Vinblastine; Xenograft Model Antitumor Assays	2009
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer letters, 2010, Sep-01, Volume: 295, Issue:1 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Everolimus; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; G1 Phase; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; raf Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2010
Promising advances in the treatment of malignant pancreatic endocrine tumors. The New England journal of medicine, 2011, Feb-10, Volume: 364, Issue:6 Topics: Antineoplastic Agents; Disease Progression; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quality of Life; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2011
Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor. Anti-cancer drugs, 2011, Volume: 22, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indoles; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Sunitinib	2011
Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome	2011
Translational medicine: Cancer lessons from mice to humans. Nature, 2011, Mar-17, Volume: 471, Issue:7338 Topics: Animals; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Everolimus; Humans; Indoles; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Sunitinib; Survival Rate; Translational Research, Biomedical	2011
Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors. Nature reviews. Clinical oncology, 2011, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2011
Recent studies show promise for treating rare pancreatic tumors. Journal of the National Cancer Institute, 2011, Apr-20, Volume: 103, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Data Interpretation, Statistical; Disease-Free Survival; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Off-Label Use; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Rare Diseases; Signal Transduction; Sirolimus; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; United States	2011
Advances in pancreatic neuroendocrine tumor treatment. The New England journal of medicine, 2011, 05-12, Volume: 364, Issue:19 Topics: Antineoplastic Agents; Blood Glucose; Diabetes Complications; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib	2011
Advances in pancreatic neuroendocrine tumor treatment. The New England journal of medicine, 2011, 05-12, Volume: 364, Issue:19 Topics: Antineoplastic Agents; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2011
Advances in pancreatic neuroendocrine tumor treatment. The New England journal of medicine, 2011, 05-12, Volume: 364, Issue:19 Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 1; Glucagonoma; Humans; Indoles; Insulinoma; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib	2011
Advances in pancreatic neuroendocrine tumor treatment. The New England journal of medicine, 2011, 05-12, Volume: 364, Issue:19 Topics: Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2011
Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report. Diabetes research and clinical practice, 2011, Volume: 93, Issue:2 Topics: Adult; Antineoplastic Agents; Critical Care; Critical Illness; Humans; Hypoglycemia; Indoles; Male; Neuroendocrine Tumors; Prednisolone; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2011
New target therapies for patients with neuroendocrine tumors of the pancreas. Expert review of gastroenterology & hepatology, 2011, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome; United States; United States Food and Drug Administration	2011
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, Dec-06, Volume: 108, Issue:49 Topics: Angiogenesis Inhibitors; Animals; Antigens, CD34; Blood Flow Velocity; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Contrast Media; Drug Evaluation, Preclinical; Humans; Immunohistochemistry; Indoles; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microbubbles; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Treatment Outcome; Tumor Burden; Ultrasonography	2011
Steve Jobs's cancer. Pancreatic neuroendocrine tumors are becoming more common (the bad news) and also more treatable (the good news). Harvard health letter, 2012, Volume: 37, Issue:3 Topics: Antineoplastic Agents; Everolimus; Famous Persons; Humans; Indoles; Liver Neoplasms; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Pyrroles; Risk Factors; Sirolimus; Sunitinib	2012
Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. The Journal of clinical investigation, 2012, Volume: 122, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Cell Hypoxia; Combined Modality Therapy; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Genetic Therapy; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Liver Neoplasms; Lymphatic Metastasis; Mice; Mice, Transgenic; Neoplasm Invasiveness; Neovascularization, Physiologic; Neuroendocrine Tumors; NF-kappa B; Pancreatic Neoplasms; Pericytes; Proto-Oncogene Proteins c-met; Pyrroles; Recombinant Proteins; Semaphorin-3A; Sunitinib; Tumor Burden; Uterine Cervical Neoplasms	2012
Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Targeted oncology, 2012, Volume: 7, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pyrroles; Sunitinib; Tomography, X-Ray Computed	2012
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. The Journal of pathology, 2012, Volume: 227, Issue:4 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Anti-Idiotypic; Disease Models, Animal; Drug Therapy, Combination; Genetic Engineering; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Vascular Endothelial Growth Factor A	2012
New treatments of pancreatic neuroendocrine tumors: why using them? How to use them? Targeted oncology, 2012, Volume: 7, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib	2012
Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; World Health Organization	2012
[More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Gastrointestinal Neoplasms; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Peptides, Cyclic; Pyrroles; Sirolimus; Somatostatin; Sunitinib	2012
Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. Journal of medical economics, 2012, Volume: 15 Suppl 1 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Everolimus; Humans; Indoles; Markov Chains; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Quality-Adjusted Life Years; Sirolimus; Sunitinib; Survival Analysis; United States	2012
Targeting neuroendocrine tumor: mixing standard options with novel therapies. Targeted oncology, 2012, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Humans; Indoles; Medical Oncology; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Temozolomide; Treatment Outcome	2012
Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role? JOP : Journal of the pancreas, 2013, Jan-10, Volume: 14, Issue:1 Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Cost-Benefit Analysis; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Outcome Assessment, Health Care; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib	2013
The genetics of neuroendocrine tumors. Seminars in oncology, 2013, Volume: 40, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Co-Repressor Proteins; DNA Helicases; Everolimus; Humans; Indoles; Molecular Chaperones; Mutation; Neuroendocrine Tumors; Nuclear Proteins; Pancreatic Neoplasms; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrroles; Sirolimus; Sunitinib; X-linked Nuclear Protein	2013
The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocrine-related cancer, 2006, Volume: 13, Issue:1 Topics: Antibiotics, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Cycle; Doxorubicin; Drug Combinations; Fatty Acids, Monounsaturated; Fluvastatin; Gastrointestinal Neoplasms; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; L-Lactate Dehydrogenase; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neuroendocrine Tumors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured	2006